Sarepta Therapeutics (NASDAQ:SRPT) saw its stock plummet in premarket trading Friday following the disclosure of a patient ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Sanofi today and set a price target of EUR100.00. The company’s shares closed last Wednesday at $95.89. According to TipRanks.com, ...

Shares of Sarepta Therapeutics plummeted nearly 30% premarket Friday following a report that a third patient has died during ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. (“Sarepta” ...

Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...

Chevron (NYSE: CVX) stock rose 3.1% after CNBC reported that the oil major has triumphed in a mediation case against rival ...

Sarepta Therapeutics shares plunged premarket on Friday after the company disclosed another patient death linked to its gene therapy programs, this time during an early-stage trial for limb-girdle ...

Shares of Sarepta Therapeutics declined 26% to $16.17 in premarket trading on Friday on media reports of a patient death after receiving one of the company's gene therapies, making it the third such ...

Shares of Sarepta Therapeutics declined 16.5% to $18.32 in premarket trading on Friday after a Bloomberg report that a patient enrolled in an early-stage study of one of the company's gene therapies ...

Sarepta Therapeutics (SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, ...

The U.S. FDA’s Oncologic Drugs Advisory Committee took up the matter of GSK plc’s relapsed/refractory multiple myeloma drug, Blenrep (belantamab mafodotin). A B-cell maturation antigen-directed ...

Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...